Insulin Aspart Sanofi (Insulin Aspart)

Insulin aspart binds to insulin receptors on muscle, fat and liver cells, activating intracellular pathways that increase glucose uptake and utilization while suppressing hepatic glucose production. Its altered amino‑acid sequence speeds absorption after subcutaneous injection, giving a rapid onset of action compared with regular human insulin.

The dose of insulin aspart is individualized. A qualified prescriber determines the total daily insulin requirement, the proportion allocated to rapid‑acting insulin, and the timing of each injection based on the patient’s carbohydrate intake, blood‑glucose patterns and lifestyle. Patients should follow the dosing instructions provided by their healthcare professional.

The safety of insulin aspart in pregnancy and lactation has not been fully established. Insulin is generally the preferred treatment for diabetes in pregnancy because it does not cross the placenta. Women who are pregnant, planning pregnancy, or breastfeeding should discuss the risks and benefits with their obstetrician and endocrinologist.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, and will request trade or institutional credentials. The sales team will then provide pricing, availability, shipping details—including cold‑chain logistics—and any necessary import documentation.

Insulin aspart shares a rapid onset and short duration with other rapid‑acting analogues such as insulin lispro and insulin glulisine. Its modified amino‑acid sequence provides slightly faster absorption than regular human insulin, offering comparable glycaemic control. Choice among these agents often depends on physician preference, patient response, and formulary considerations.

Insulin aspart should be stored in a refrigerator at 2‑8 °C (36‑46 °F). Keep the vial in its original carton to protect from light, and do not freeze. Once in use, the vial may be kept at controlled room temperature (up to 30 °C) for up to 28 days, but any cloudiness or particles indicate it should be discarded.

Insulin aspart is administered by subcutaneous injection using a sterile needle or an insulin pen device. It is typically injected into the abdomen, thigh or upper arm, rotating sites with each dose to reduce lipodystrophy risk. Injections are given shortly before meals, usually within 5‑10 minutes, to match carbohydrate intake.

The most serious risks include severe hypoglycaemia, which can cause confusion, loss of consciousness or seizures, and rare anaphylactic reactions that require immediate medical attention. Patients should be educated on recognising early signs of low blood glucose and have rapid‑acting carbohydrate sources readily available.

Insulin aspart should not be used by individuals with a known hypersensitivity to insulin aspart or any of its excipients. It is also contraindicated in patients with severe hypoglycaemia unresponsive to treatment. Clinicians should assess each patient’s medical history before initiating therapy.